• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Keystone Nano wins FDA nod for nanoliposome cancer treatment

January 5, 2017 By Sarah Faulkner

Keystone Nano wins FDA nod for nanoliposome cancer treatmentKeystone Nano said today that the FDA approved its investigational new drug application for the ceramide nanoliposome as a treatment for solid tumors. The company will launch a phase I trial at 3 sites to evaluate safe dosing levels and the product’s efficacy as a cancer therapy.

Ceramide is a lipid that has demonstrated efficacy in liver cancer, breast cancer, leukemia and pancreatic cancer. Preclinical evidence has shown that Keystone’s nanoliposome is an effective delivery system for the bioactive compound, targeting cancer cells and ignoring healthy cells.

“This approval represents the conclusion of 1 phase of developing ceramide, a truly novel anti-cancer agent, and the beginning of the very important human testing phase,” CEO Jeff Davidson said in prepared remarks.  “We are excited by the efficacy and lack of toxicity ceramide nanoliposome has shown in preclinical testing, and we look forward to continuing to evaluate ceramide nanoliposome for human use.  This is a significant step forward in the development of ceramide nanoliposome for the treatment of cancer.”

Keystone reported that the phase I trial will recruit patients with solid tumors, while the phase II study will focus on liver cancer. The State College, Penn.-based company was granted orphan drug status for its ceramide nanoliposomes in October last year.

“The anti-cancer activity of ceramide has long been known in the laboratory,” VP of research Mylisa Parette added. “Until now, however, no-one has had an effective method for delivery of ceramide, which is insoluble and has an extremely short half-life in the body.  The proprietary formulation we are evaluating uses ceramide integrated into the membrane of a nanoliposome to overcome these barriers and allow us to exploit the novel properties of ceramide as an anti-cancer therapy.”

Filed Under: Featured, Food & Drug Administration (FDA), Nanoparticles, Oncology, Regulatory/Compliance Tagged With: Keystone Nano

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS